Taken together, these results indicate that reduced expression of both E-cadherin and DSG2 is significantly associated with BCR in prostate cancer, but that DSG2 alone, as previously reported by our group 15 may be the most useful prognostic marker. The gene discussed is BCR; the disease is prostate carcinoma.